 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
137 News |  |
| «12 |
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Phase classification: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia (clinicaltrials.gov) - Nov 19, 2020
P1, N=48, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Phase classification: P1/2 --> P1
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Review, Journal: Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. (Pubmed Central) - Oct 21, 2020
In addition, we review the BPLTTC analysis on blood pressure treatment across blood pressure levels and CVD status and discuss findings from the BRACE CORONA study that examined continuing versus suspending angiotensin-converting enzyme inhibitor or angiotensin receptor blockers in patients on these antihypertensive medications who were hospitalized with COVID-19 infection. The studies presented at the 2020 digital ESC Congress highlight the continuing advancements in the field of CVD prevention.
- |||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) (clinicaltrials.gov) - Sep 30, 2020
P2b, N=260, Recruiting, Sponsor: Pfizer
The studies presented at the 2020 digital ESC Congress highlight the continuing advancements in the field of CVD prevention. Not yet recruiting --> Recruiting
- || vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides (clinicaltrials.gov) - Aug 27, 2020
P1, N=12, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P2b trial: A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) (clinicaltrials.gov) - Aug 17, 2020
P2b, N=260, Not yet recruiting, Sponsor: Pfizer
- |||| P3 data: Volanesorsen not approved in US 🤷🏻♂️; phase 3 are ongoing with AKCEA-APOCIII-Lrx, Evinacumab & IONIS-ANGPTL3-Lrx; Alipogene no longer marketed. I think that there are no more options... (Twitter) - Jul 23, 2020
- || vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P1 trial: Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides (clinicaltrials.gov) - Jul 6, 2020
P1, N=12, Not yet recruiting, Sponsor: Pfizer
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis
[VIRTUAL] Selective Targeting of Angiopoietin-Like 3 (ANGPTL3) via the Second-Generation Antisense Oligonucleotide (ASO) ISIS-703802 (AKCEA-ANGPTL3-LRx) in Subjects with Familial Partial Lipodystrophy (FPLD) () - May 18, 2020 - Abstract #ADA2020ADA_3269;
In addition, HbA1c showed a modest mean absolute reduction of 0.2±1.0 % The drug was well tolerated and there were no new safety signals observed. Although a small study, these results suggest that targeting ANGPTL3 in patients with FPLD could successfully address metabolic dyslipidemia.
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis
[VIRTUAL] Selective Targeting of Angiopoietin-Like 3 (ANGPTL3) via the Second-Generation Antisense Oligonucleotide (ASO) ISIS-703802 (AKCEA-ANGPTL3-LRx) in Subjects with Familial Partial Lipodystrophy (FPLD) () - May 18, 2020 - Abstract #ADA2020ADA_1831;
In addition, HbA1c showed a modest mean absolute reduction of 0.2±1.0 % The drug was well tolerated and there were no new safety signals observed. Although a small study, these results suggest that targeting ANGPTL3 in patients with FPLD could successfully address metabolic dyslipidemia.
- ||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial completion: Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Mar 13, 2020
P2, N=105, Completed, Sponsor: Akcea Therapeutics
Although a small study, these results suggest that targeting ANGPTL3 in patients with FPLD could successfully address metabolic dyslipidemia. Active, not recruiting --> Completed
- | vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Sep 27, 2019
P2, N=144, Active, not recruiting, Sponsor: Akcea Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Nov 2019
- | vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial completion, Trial primary completion date: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) (clinicaltrials.gov) - Sep 12, 2019
P2, N=4, Completed, Sponsor: Akcea Therapeutics
Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Nov 2019 Active, not recruiting --> Completed | Trial primary completion date: Apr 2019 --> Jul 2019
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial completion: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) (clinicaltrials.gov) - Apr 25, 2019
P2, N=3, Completed, Sponsor: Akcea Therapeutics
Active, not recruiting --> Completed | Trial primary completion date: Apr 2019 --> Jul 2019 Active, not recruiting --> Completed
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) (clinicaltrials.gov) - Jan 17, 2019
P2, N=3, Active, not recruiting, Sponsor: Akcea Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Apr 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial withdrawal: Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (clinicaltrials.gov) - Dec 3, 2018
P2, N=0, Withdrawn, Sponsor: Akcea Therapeutics
Recruiting --> Active, not recruiting | Trial completion date: Apr 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Recruiting --> Withdrawn
- | vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment closed: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) (clinicaltrials.gov) - Aug 1, 2018
P2, N=3, Active, not recruiting, Sponsor: Akcea Therapeutics
Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) (clinicaltrials.gov) - Jul 2, 2018
P2, N=3, Recruiting, Sponsor: Akcea Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P2 trial: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) (clinicaltrials.gov) - May 1, 2018
P2, N=3, Not yet recruiting, Sponsor: Akcea Therapeutics
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (clinicaltrials.gov) - Apr 23, 2018
P2, N=3, Recruiting, Sponsor: Akcea Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P2 trial: Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (clinicaltrials.gov) - Mar 7, 2018
P2, N=3, Not yet recruiting, Sponsor: Akcea Therapeutics
- | vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia (clinicaltrials.gov) - Feb 13, 2018
P1/2, N=48, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Aug 2017 --> Jun 2017 | Trial primary completion date: Jun 2017 --> Apr 2017
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) (clinicaltrials.gov) - Feb 8, 2018
P2, N=3, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Completed | Trial completion date: Aug 2017 --> Jun 2017 | Trial primary completion date: Jun 2017 --> Apr 2017 Trial primary completion date: Apr 2018 --> Jul 2018 | Trial completion date: Jul 2018 --> Sep 2018 | Initiation date: Dec 2017 --> Dec 2017
- |||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jan 3, 2018
P2, N=144, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial primary completion date: Apr 2018 --> Jul 2018 | Trial completion date: Jul 2018 --> Sep 2018 | Initiation date: Dec 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- ||||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P2 trial: Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 13, 2017
P2, N=144, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Enrollment open: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) (clinicaltrials.gov) - Dec 8, 2017
P2, N=3, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P2 trial: Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) (clinicaltrials.gov) - Dec 4, 2017
P2, N=3, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- ||||| vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
New P1/2 trial: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia (clinicaltrials.gov) - Mar 16, 2016
P1/2, N=61, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.